유전자 치료 CDMO 시장 규모와 예측(2021-2034년) : 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 - 서비스 유형별, 최종사용자, 지역별

The gene therapy CDMO market size is expected to grow from US$ 2.60 billion in 2025 to US$ 14.17 billion by 2034; it is projected to register a CAGR of 20.3% during 2026-2034. The increasing prevalence of chronic and genetic diseases, surging regulatory approvals and commercialization, and growing popularity of outsourcing gene therapy manufacturing by companies are noteworthy factors contributing to the expansion of the gene therapy CDMO market size. Additionally, the growing demand for personalized and rare disease therapies are projected to bring new gene therapy CDMO market trends in the near future.

The market experiences a transformation because automation and digitalization bring better efficiency and scalability and improved quality control. The technologies solve complex challenges which arise from developing personalized therapies because they minimize the need for human participation while they streamline the procedures which handle viral vector production and cell expansion. CDMOs implement process analytical technologies to monitor their operations in real time which allows them to adjust their processing methods while maintaining simultaneous production of multiple items. Digital twins use their predictive capabilities to forecast how cells will react under different testing conditions, which helps to improve factory processes. The combination of Sartorius's MODDE software with Ambr 15 bioreactors demonstrates how digital twin technology enables optimization through virtual twin systems. The process of viral vector optimization achieved a significant reduction in experimental duration to three weeks from eight weeks while it generated a tenfold rise in infectious titer through precise adjustment of pH and cell density parameters.

The use of machine learning algorithms together with predictive capabilities enables CDMOs to implement proactive measures which decrease operational interruptions while enhancing the therapeutic product quality and quantity. In October 2024, OmniaBio opened its new commercial-ready manufacturing facility and AI center of excellence in Hamilton, Ontario, Canada. The facility which covers 100,000 square feet stands among the biggest CDMOs which focus on manufacturing cell and gene therapies.

The regulatory requirements for gene therapy manufacturing necessitate organizations to collect and analyze extensive data throughout their manufacturing processes. AI and digital tools enable seamless data integration, ensuring that all necessary documentation is complete and accurate for regulatory review. CDMOs that use AI together with digital platforms can effectively handle the complex nature of regulatory submission processes while they maintain compliance with changing industry requirements.

Automation together with artificial intelligence and digital analytics systems has become the key approach for CDMOs to achieve operational efficiency through their implementation, thereby emerging as a significant trend in the gene therapy CDMO market.

End User-Based Insights

Based on end user, the gene therapy CDMO market is segmented into pharmaceutical companies, biopharmaceutical companies, and other end users. The biopharmaceutical companies segment held the largest gene therapy CDMO market share in 2025. The gene therapy CDMO market is mainly controlled by biopharmaceutical companies which include small biotech firms and startup companies that need outside help for their product development and manufacturing activities. The company's expansion results from its incomplete internal capacity combined with expensive research and development expenses and the difficult nature of gene therapy treatments which need special medical facilities and expert technical knowledge that the company usually does not possess. The company uses outsourcing to improve its clinical pipeline development process while maintaining its budget for research and development activities. The expanding gene therapy pipeline, with thousands of assets in development, creates increasing demand as biotechs require trustworthy partners for their needs in viral vector production and process optimization and GMP manufacturing services. Key examples include collaborations with leading CDMOs like Lonza and Catalent which support numerous biotech programs in oncology and rare diseases. Gilead Sciences (via Kite Pharma) and Amgen have also used CDMO services for their advanced development of gene-modified therapies. The biotechs use CDMO services to overcome their regulatory challenges which enables them to bring products to market faster, thereby fueling the gene therapy CDMO market growth.

The World Health Organization and Australian Institute of Health and Welfare are among the primary and secondary sources referred to while preparing the gene therapy CDMO market report.

Table Of Contents

1. Executive Summary

• 1.1 Analyst Market Outlook
• 1.2 Market Attractiveness

2. Gene Therapy CDMO Market Landscape

• 2.1 Overview
• 2.2 Value Chain Analysis
• 2.3 Supply Chain Analysis
  • 2.3.1 List of Manufacturers/Suppliers
  • 2.3.2 List of Potential Customers (Upto 50)
• 2.4 Porter's Five Force Analysis
• 2.5 PEST Analysis
• 2.6 Import-Export Analysis for Key Countries (As per the nearest HS Code)
  • 2.6.1 Import-Export Analysis for Key Countries
• 2.7 Impact of Artificial Intelligence (AI)
• 2.8 Product or Technology Roadmap
• 2.9 Sustainability and ESG Trends
• 2.10 Patent Analysis
• 2.11 Regulatory Framework

3. Competitive Landscape

• 3.1 Company Benchmarking by Key Players
• 3.2 Market Share Analysis, 2025 - By Key Players
• 3.3 Market Concentration

4. Gene Therapy CDMO Market - Key Industry Dynamics

• 4.1 Market Drivers
  • 4.1.1 Increasing Prevalence of Chronic and Genetic Diseases
  • 4.1.2 Surging Regulatory Approvals and Commercialization
  • 4.1.3 Growing Popularity of Outsourcing Gene Therapy Manufacturing by Companies
• 4.2 Market Restraints
  • 4.2.1 High Manufacturing Costs
  • 4.2.2 Complexities in Manufacturing Processes
  • 4.2.3 Complex Regulatory and Compliance Requirements
• 4.3 Market Opportunities
  • 4.3.1 Increased Clinical Trials for Innovative Therapies
  • 4.3.2 Strategic Initiatives by Companies
  • 4.3.3 Expansion of Commercial Manufacturing Services
• 4.4 Future Trends
  • 4.4.1 Advanced Automation and Digitalization
  • 4.4.2 Personalized and Rare Disease Therapies Demand
  • 4.4.3 Scalable Viral Vector and Next Gen Production Technologies
• 4.5 Impact of Drivers and Restraints

5. Gene Therapy CDMO Market - Global Market Analysis

• 5.1 Gene Therapy CDMO Market Revenue (US$ Million), 2021-2034
• 5.2 Gene Therapy CDMO Market Forecast and Analysis

6. Gene Therapy CDMO Market Revenue Analysis -Service Type

• 6.1 Gene Therapy CDMO Market Forecasts and Analysis by Service Type
  • 6.1.1 Drug Development and Manufacturing
    • 6.1.1.1 Overview
    • 6.1.1.2 Drug Development and Manufacturing: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
  • 6.1.2 Testing and Regulatory Services
    • 6.1.2.1 Overview
    • 6.1.2.2 Testing and Regulatory Services: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
  • 6.1.3 Other Service Types
    • 6.1.3.1 Overview
    • 6.1.3.2 Other Service Types: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)

7. Gene Therapy CDMO Market Revenue Analysis -End User

• 7.1 Gene Therapy CDMO Market Forecasts and Analysis by End User
  • 7.1.1 Pharmaceutical Companies
    • 7.1.1.1 Overview
    • 7.1.1.2 Pharmaceutical Companies: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
  • 7.1.2 Biopharmaceutical Companies
    • 7.1.2.1 Overview
    • 7.1.2.2 Biopharmaceutical Companies: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)
  • 7.1.3 Other End Users
    • 7.1.3.1 Overview
    • 7.1.3.2 Other End Users: Gene Therapy CDMO Market -Revenue, 2021-2034 (US$ Million)

8. Gene Therapy CDMO Market - Geographical Analysis

• 8.1 North America
  • 8.1.1 North America Gene Therapy CDMO Market Overview
  • 8.1.2 North America: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • 8.1.3 North America: Gene Therapy CDMO Market- By Segmentation
    • 8.1.3.1 Service Type
    • 8.1.3.2 End User
  • 8.1.4 North America: Gene Therapy CDMO Market Breakdown by Countries
    • 8.1.4.1 United States Market
      • 8.1.4.1.1 United States: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.1.4.1.2 United States: Gene Therapy CDMO Market- By Segmentation
        • 8.1.4.1.2.1 Service Type
        • 8.1.4.1.2.2 End User
    • 8.1.4.2 Canada Market
      • 8.1.4.2.1 Canada: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.1.4.2.2 Canada: Gene Therapy CDMO Market- By Segmentation
        • 8.1.4.2.2.1 Service Type
        • 8.1.4.2.2.2 End User
    • 8.1.4.3 Mexico Market
      • 8.1.4.3.1 Mexico: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.1.4.3.2 Mexico: Gene Therapy CDMO Market- By Segmentation
        • 8.1.4.3.2.1 Service Type
        • 8.1.4.3.2.2 End User
• 8.2 Europe
  • 8.2.1 Europe Gene Therapy CDMO Market Overview
  • 8.2.2 Europe: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • 8.2.3 Europe: Gene Therapy CDMO Market- By Segmentation
    • 8.2.3.1 Service Type
    • 8.2.3.2 End User
  • 8.2.4 Europe: Gene Therapy CDMO Market Breakdown by Countries
    • 8.2.4.1 Germany Market
      • 8.2.4.1.1 Germany: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.2.4.1.2 Germany: Gene Therapy CDMO Market- By Segmentation
        • 8.2.4.1.2.1 Service Type
        • 8.2.4.1.2.2 End User
    • 8.2.4.2 United Kingdom Market
      • 8.2.4.2.1 United Kingdom: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.2.4.2.2 United Kingdom: Gene Therapy CDMO Market- By Segmentation
        • 8.2.4.2.2.1 Service Type
        • 8.2.4.2.2.2 End User
    • 8.2.4.3 France Market
      • 8.2.4.3.1 France: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.2.4.3.2 France: Gene Therapy CDMO Market- By Segmentation
        • 8.2.4.3.2.1 Service Type
        • 8.2.4.3.2.2 End User
    • 8.2.4.4 Italy Market
      • 8.2.4.4.1 Italy: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.2.4.4.2 Italy: Gene Therapy CDMO Market- By Segmentation
        • 8.2.4.4.2.1 Service Type
        • 8.2.4.4.2.2 End User
    • 8.2.4.5 Spain Market
      • 8.2.4.5.1 Spain: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.2.4.5.2 Spain: Gene Therapy CDMO Market- By Segmentation
        • 8.2.4.5.2.1 Service Type
        • 8.2.4.5.2.2 End User
    • 8.2.4.6 Rest of Europe Market
      • 8.2.4.6.1 Rest of Europe: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.2.4.6.2 Rest of Europe: Gene Therapy CDMO Market- By Segmentation
        • 8.2.4.6.2.1 Service Type
        • 8.2.4.6.2.2 End User
• 8.3 Asia Pacific
  • 8.3.1 Asia Pacific Gene Therapy CDMO Market Overview
  • 8.3.2 Asia Pacific: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • 8.3.3 Asia Pacific: Gene Therapy CDMO Market- By Segmentation
    • 8.3.3.1 Service Type
    • 8.3.3.2 End User
  • 8.3.4 Asia Pacific: Gene Therapy CDMO Market Breakdown by Countries
    • 8.3.4.1 China Market
      • 8.3.4.1.1 China: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.3.4.1.2 China: Gene Therapy CDMO Market- By Segmentation
        • 8.3.4.1.2.1 Service Type
        • 8.3.4.1.2.2 End User
    • 8.3.4.2 Japan Market
      • 8.3.4.2.1 Japan: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.3.4.2.2 Japan: Gene Therapy CDMO Market- By Segmentation
        • 8.3.4.2.2.1 Service Type
        • 8.3.4.2.2.2 End User
    • 8.3.4.3 India Market
      • 8.3.4.3.1 India: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.3.4.3.2 India: Gene Therapy CDMO Market- By Segmentation
        • 8.3.4.3.2.1 Service Type
        • 8.3.4.3.2.2 End User
    • 8.3.4.4 Australia Market
      • 8.3.4.4.1 Australia: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.3.4.4.2 Australia: Gene Therapy CDMO Market- By Segmentation
        • 8.3.4.4.2.1 Service Type
        • 8.3.4.4.2.2 End User
    • 8.3.4.5 South Korea Market
      • 8.3.4.5.1 South Korea: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.3.4.5.2 South Korea: Gene Therapy CDMO Market- By Segmentation
        • 8.3.4.5.2.1 Service Type
        • 8.3.4.5.2.2 End User
    • 8.3.4.6 Rest of APAC Market
      • 8.3.4.6.1 Rest of APAC: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.3.4.6.2 Rest of APAC: Gene Therapy CDMO Market- By Segmentation
        • 8.3.4.6.2.1 Service Type
        • 8.3.4.6.2.2 End User
• 8.4 Middle East and Africa
  • 8.4.1 Middle East and Africa Gene Therapy CDMO Market Overview
  • 8.4.2 Middle East and Africa: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • 8.4.3 Middle East and Africa: Gene Therapy CDMO Market- By Segmentation
    • 8.4.3.1 Service Type
    • 8.4.3.2 End User
  • 8.4.4 Middle East and Africa: Gene Therapy CDMO Market Breakdown by Countries
    • 8.4.4.1 Saudi Arabia Market
      • 8.4.4.1.1 Saudi Arabia: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.4.4.1.2 Saudi Arabia: Gene Therapy CDMO Market- By Segmentation
        • 8.4.4.1.2.1 Service Type
        • 8.4.4.1.2.2 End User
    • 8.4.4.2 South Africa Market
      • 8.4.4.2.1 South Africa: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.4.4.2.2 South Africa: Gene Therapy CDMO Market- By Segmentation
        • 8.4.4.2.2.1 Service Type
        • 8.4.4.2.2.2 End User
    • 8.4.4.3 United Arab Emirates Market
      • 8.4.4.3.1 United Arab Emirates: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.4.4.3.2 United Arab Emirates: Gene Therapy CDMO Market- By Segmentation
        • 8.4.4.3.2.1 Service Type
        • 8.4.4.3.2.2 End User
    • 8.4.4.4 Rest of Middle East and Africa Market
      • 8.4.4.4.1 Rest of Middle East and Africa: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.4.4.4.2 Rest of Middle East and Africa: Gene Therapy CDMO Market- By Segmentation
        • 8.4.4.4.2.1 Service Type
        • 8.4.4.4.2.2 End User
• 8.5 South and Central America
  • 8.5.1 South and Central America Gene Therapy CDMO Market Overview
  • 8.5.2 South and Central America: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
  • 8.5.3 South and Central America: Gene Therapy CDMO Market- By Segmentation
    • 8.5.3.1 Service Type
    • 8.5.3.2 End User
  • 8.5.4 South and Central America: Gene Therapy CDMO Market Breakdown by Countries
    • 8.5.4.1 Brazil Market
      • 8.5.4.1.1 Brazil: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.5.4.1.2 Brazil: Gene Therapy CDMO Market- By Segmentation
        • 8.5.4.1.2.1 Service Type
        • 8.5.4.1.2.2 End User
    • 8.5.4.2 Argentina Market
      • 8.5.4.2.1 Argentina: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.5.4.2.2 Argentina: Gene Therapy CDMO Market- By Segmentation
        • 8.5.4.2.2.1 Service Type
        • 8.5.4.2.2.2 End User
    • 8.5.4.3 Rest of South and Central America Market
      • 8.5.4.3.1 Rest of South and Central America: Gene Therapy CDMO Market Revenue and Forecasts, 2021-2034 (US$ Million)
      • 8.5.4.3.2 Rest of South and Central America: Gene Therapy CDMO Market- By Segmentation
        • 8.5.4.3.2.1 Service Type
        • 8.5.4.3.2.2 End User

9. Gene Therapy CDMO Market Industry Landscape

10. Gene Therapy CDMO Market - Key Company Profiles

• 10.1 WuXi Biologics Inc
  • 10.1.1 Key Facts
  • 10.1.2 Business Description
  • 10.1.3 Products and Services
  • 10.1.4 Financial Overview
  • 10.1.5 SWOT Analysis
  • 10.1.6 Key Developments
• 10.2 Charles River Laboratories International Inc
  • 10.2.1 Key Facts
  • 10.2.2 Business Description
  • 10.2.3 Products and Services
  • 10.2.4 Financial Overview
  • 10.2.5 SWOT Analysis
  • 10.2.6 Key Developments
• 10.3 Catalent Inc
  • 10.3.1 Key Facts
  • 10.3.2 Business Description
  • 10.3.3 Products and Services
  • 10.3.4 Financial Overview
  • 10.3.5 SWOT Analysis
  • 10.3.6 Key Developments
• 10.4 Lonza Group AG
  • 10.4.1 Key Facts
  • 10.4.2 Business Description
  • 10.4.3 Products and Services
  • 10.4.4 Financial Overview
  • 10.4.5 SWOT Analysis
  • 10.4.6 Key Developments
• 10.5 National Resilience Inc
  • 10.5.1 Key Facts
  • 10.5.2 Business Description
  • 10.5.3 Products and Services
  • 10.5.4 Financial Overview
  • 10.5.5 SWOT Analysis
  • 10.5.6 Key Developments
• 10.6 Thermo Fisher Scientific Inc
  • 10.6.1 Key Facts
  • 10.6.2 Business Description
  • 10.6.3 Products and Services
  • 10.6.4 Financial Overview
  • 10.6.5 SWOT Analysis
  • 10.6.6 Key Developments
• 10.7 AGC Biologics AS
  • 10.7.1 Key Facts
  • 10.7.2 Business Description
  • 10.7.3 Products and Services
  • 10.7.4 Financial Overview
  • 10.7.5 SWOT Analysis
  • 10.7.6 Key Developments
• 10.8 Takara Bio Inc
  • 10.8.1 Key Facts
  • 10.8.2 Business Description
  • 10.8.3 Products and Services
  • 10.8.4 Financial Overview
  • 10.8.5 SWOT Analysis
  • 10.8.6 Key Developments
• 10.9 FUJIFILM Holdings Corp
  • 10.9.1 Key Facts
  • 10.9.2 Business Description
  • 10.9.3 Products and Services
  • 10.9.4 Financial Overview
  • 10.9.5 SWOT Analysis
  • 10.9.6 Key Developments
• 10.10 SK pharmteco Inc
  • 10.10.1 Key Facts
  • 10.10.2 Business Description
  • 10.10.3 Products and Services
  • 10.10.4 Financial Overview
  • 10.10.5 SWOT Analysis
  • 10.10.6 Key Developments

11. Appendix

• 11.1 Glossary
• 11.4 Research Methodology and Approach
  • 11.4.1 Secondary Research
  • 11.4.2 Primary Research
  • 11.4.3 Market Estimation Approach
    • 11.4.3.1 Supply Side Analysis
    • 11.4.3.2 Demand Side Analysis
  • 11.4.4 Research Assumptions and Limitations
  • 11.4.5 Currency Conversion
• 11.5 About The Insight Partners
• 11.6 Market Intelligence Cloud